The GDI2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the gene encoding GDP dissociation inhibitor 2 (GDI2) in the human Burkitt lymphoma-derived Raji B lymphocyte line. This polyclonal knockout model provides a heterogeneous loss-of-function system for studying the role of GDI2 in intracellular membrane trafficking and B cell biology. The use of polyclonal populations avoids clonal selection biases and maintains genetic diversity, making it suitable for pooled functional screens and bulk biochemical analyses where population-level effects are prioritized.
Raji cells constitute an Epstein-Barr virus (EBV)-transformed B lymphoblastoid line originally established from a Burkitt lymphoma patient. They are widely employed as a model system for B cell malignancies and immune signaling due to their robust growth characteristics and retention of key B cell features, including surface B cell receptor (BCR) expression and the machinery for antigen presentation via major histocompatibility complex class II (MHC-II) molecules. Their transformed nature and EBV positivity also render them valuable for studying oncogenic mechanisms in lymphoma.
GDI2 centrally regulates the Rab GTPase cycle by extracting and solubilizing GDP-bound Rab proteins from intracellular membranes, thereby maintaining a cytosolic reservoir of inactive Rabs and controlling their membrane association dynamics. Among its critical targets are the early endosomal Rab5, late endosomal Rab7, and recycling endosomal Rab11, which collectively govern endocytosis, endosomal sorting, lysosomal degradation, and receptor recycling. GDI2 interacts directly with the GDP-bound forms of these Rab GTPases and is antagonized by GDI displacement factors such as Yip3/Pra1 that promote Rab membrane recruitment. Downstream effectors of this network include SNARE proteins, early endosome antigen 1 (EEA1), and lysosomal-associated membrane protein 1 (LAMP1), linking GDI2 to fundamental trafficking and organelle identity pathways.
In the context of Raji B cells, disruption of GDI2 is anticipated to perturb endocytic recycling and exocytic pathways, leading to altered surface levels of receptors such as BCR and MHC-II. This may impact antigen presentation efficiency and downstream immune signaling cascades, which are often dysregulated in B cell malignancies. By impairing Rab-dependent trafficking, GDI2 knockout could illuminate mechanisms of lymphomagenesis related to aberrant receptor trafficking and signal transduction, offering a physiologically relevant model for studying the intersection of membrane dynamics and oncogenic transformation.
This knockout cell product supports a wide range of research applications, including quantitative analysis of Rab GTPase cycling by co-immunoprecipitation with Rab5, Rab7, or Rab11; assessment of BCR and MHC-II surface expression via flow cytometry; Rab protein localization by immunofluorescence; and endocytosis/recycling assays using labeled ligands. Additionally, the polyclonal knockout population is suitable for RNA-seq-based transcriptomic profiling and pooled drug sensitivity screens to identify vulnerabilities in GDI2-deficient B cell lymphomas. For further technical information, please contact Ascent Research.
